Key Highlights

  • Net loss for the quarter ended September 30, 2026 was USD 20.3 million, or USD 0.32 per share, compared with USD 17.0 million, or USD 0.30, in the prior-year quarter.
  • Research and development expense rose to USD 16.9 million from USD 14.6 million, including USD 3.3 million for myotonic dystrophy type-1, which had no spending a year earlier.
  • Combined cash, cash equivalents and Investment securities were USD 208.6 million on September 30, 2026, down USD 11.2 million from December 31, 2025.
  • The company sold 3,140,522 shares through its at-the-market program in nine months for net proceeds of about USD 37.1 million and plans to raise the program limit to USD 200.0 million.

Clinical Spending Lifts the Loss as Interest Income Slips

Design Therapeutics (NASDAQ:DSGN) filed its Quarterly Report on November 4, 2026. The clinical-stage company develops GeneTAC small molecules aimed at inherited diseases caused by nucleotide repeat expansions, including Friedreich ataxia, myotonic dystrophy type-1 and Fuchs endothelial corneal dystrophy. Operating expenses were USD 22.2 million against USD 19.3 million, with general and administrative costs of USD 5.3 million. Interest income eased to USD 1.9 million from USD 2.3 million. Nine-month net loss was USD 58.1 million, or USD 0.93 per share, against USD 53.8 million, or USD 0.95, as the weighted-average share count rose.

RESTORE-FA Data and a Shifting Program Mix

Friedreich ataxia spending was USD 4.7 million in the quarter, while spending on the eye disease program fell to USD 0.5 million from USD 1.6 million. In May 2026 the company reported four-week data from its Phase 1/2 RESTORE-FA trial of DT-216P2, with a mean 6.4-point improvement on a Friedreich ataxia rating scale in the four patients at the 1 mpk dose. Whole blood frataxin messenger RNA rose 65% from baseline. The company plans to update registrational plans in the fourth quarter of 2026 and expects 12-week data in the first quarter of 2027. In its eye disease program, the company completed baseline assessments on about 250 patients in an observational study and selected about 100 for follow-up visits. The RESTORE-FA cohort is small, so results may not hold in larger groups.

Cash Runway and the Larger ATM Program

Of the USD 208.6 million, cash and cash equivalents were USD 15.3 million and investment securities USD 193.4 million. Nine-month operating cash use was USD 47.3 million. Management says existing resources should fund planned expenses for more than the next 12 months following the filing. The company had USD 36.4 million left on its at-the-market program as of September 30, 2026, and intends to file a supplement raising the limit to USD 200.0 million under a USD 300.0 million shelf. Selling shares gradually adds to the 63,785,058 shares outstanding and can dilute existing holders. Losses are expected to continue for the foreseeable future.

Where Things Stand

USD 208.6 million goes about as far as management states: more than 12 months of planned spending, with no longer horizon given in the filing. Design Therapeutics (NASDAQ:DSGN) used USD 47.3 million of operating cash in nine months and is leaning on its at-the-market program, so further share sales are likely to be part of the funding path. Next markers are the registrational plan update in the fourth quarter of 2026 and 12-week RESTORE-FA data in the first quarter of 2027.